Company

Lysogene S.A.

France-based Lysogene S.A. develops gene therapies for rare neurodegenerative diseases.

About

Lysogene S.A. develops gene therapies for rare neurodegenerative diseases, targeting conditions that currently lack effective treatments. Founded in 2009 and headquartered in France, the company is led by founder and CEO Karen Aiach. In February 2017 it raised EUR 22.6 million in an IPO, selling 12.08 million shares at EUR 6.8 each. It has completed seven deals to date and is at Series A stage.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in